Corgentech is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has four drug candidates in clinical development for multiple potential indications, the most advanced of which, 3268, has completed Phase 3 clinical trials. To reflect the company's core focus on novel pain management therapies, the board of directors recently voted to change the company name to Anesiva. If approved by stockholders at the annual meeting on June 21, 2006, the name change will become effective immediately thereafter and the stock is anticipated to trade under the Nasdaq symbol: ANSV. Corgentech is based in South San Francisco, CA.
| Website | http://www.corgentech.com |
| Revenue | $9.4 million |
| Employees | View employees |
| Founded | 1999 |
| Address | 650 Gateway Blvd, South San Francisco, California 94080, US |
| Phone | +1 650-624-9600 |
| Industry | Business Services General, Pharmaceuticals, Business Services, Therapeutic Devices |
| Competitors | Xenon Pharmaceuticals Inc., Viking Therapeutics, Inc., Sparrow Pharmaceuticals, Inc., Athersys, CureVac, TransMedics, Inc., Zymeworks Inc., Cellectis, Novavax, Adaptimmune +36 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies, SIC Code 73 Companies, SIC Code 737 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies |
Looking for a particular Corgentech Inc. employee's phone or email?
Corgentech Inc. Questions
The Corgentech Inc. annual revenue was $9.4 million in 2026.
Corgentech Inc. is based in South San Francisco, California.
The NAICS codes for Corgentech Inc. are [325, 54, 541, 3254, 32].
The SIC codes for Corgentech Inc. are [283, 28, 73, 737].
